{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=CHRONIC+DISEASE&page=11", "query": { "condition": "CHRONIC DISEASE", "page": 11 }, "page_size": 10 }, "pagination": { "page": 11, "page_size": 10, "total_count": 11562, "total_pages": 1157, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=CHRONIC+DISEASE&page=12&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=CHRONIC+DISEASE&page=10&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-31T12:29:26.815Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03656926", "title": "Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Double Lung Transplant (BOSTON-2)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Bronchiolitis Obliterans", "Chronic Rejection of Lung Transplant", "Lung Transplant Rejection", "Lung Transplant; Complications", "Lung Transplant Failure and Rejection", "Chronic Lung Allograft Dysfunction" ], "interventions": [ { "name": "Liposomal Cyclosporine A", "type": "DRUG" }, { "name": "Standard of Care", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Zambon SpA", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 169, "start_date": "2019-03-26", "completion_date": "2024-03-12", "has_results": true, "last_update_posted_date": "2026-02-10", "last_synced_at": "2026-10-31T12:29:26.815Z", "location_count": 21, "location_summary": "Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 16 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03656926" }, { "nct_id": "NCT01435226", "title": "GS-5885, GS-9451, Tegobuvir and Ribovirin in Treatment-Experienced Subjects With Chronic Genotype 1a Or 1b Hepatitis C Virus (HCV) Infection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C, Chronic" ], "interventions": [ { "name": "GS-5885", "type": "DRUG" }, { "name": "GS-9451", "type": "DRUG" }, { "name": "tegobuvir", "type": "DRUG" }, { "name": "placebo to match tegobuvir", "type": "DRUG" }, { "name": "placebo to match RBV", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 170, "start_date": "2011-09", "completion_date": "2013-07", "has_results": false, "last_update_posted_date": "2013-12-17", "last_synced_at": "2026-10-31T12:29:26.815Z", "location_count": 37, "location_summary": "Tucson, Arizona • Anaheim, California • Beverly Hills, California + 30 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Anaheim", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Coronado", "state": "California" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01435226" }, { "nct_id": "NCT04301076", "title": "Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment (\"EPOCH\") for Adult T-Cell Leukemia-Lymphoma (ATLL)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Adult T-Cell Leukemia/Lymphoma", "Adult T-Cell Leukemia/Lymphoma", "Chronic Adult T-Cell Leukemia/Lymphoma", "HTLV-1 Infection" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Vincristine Sulfate", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2021-08-31", "completion_date": "2027-06-30", "has_results": false, "last_update_posted_date": "2026-10-29", "last_synced_at": "2026-10-31T12:29:26.815Z", "location_count": 19, "location_summary": "Atlanta, Georgia • City of Saint Peters, Missouri • Creve Coeur, Missouri + 11 more", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "City of Saint Peters", "state": "Missouri" }, { "city": "Creve Coeur", "state": "Missouri" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT04301076" }, { "nct_id": "NCT04615091", "title": "Non-invasive Methods and Surgical Risk Stratification in Cirrhotics Undergoing Elective Extrahepatic Surgery", "overall_status": "UNKNOWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Advanced Chronic Liver Disease", "Surgery--Complications" ], "interventions": [], "intervention_types": [], "sponsor": "Azienda Ospedaliera Universitaria Integrata Verona", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 250, "start_date": "2020-08-30", "completion_date": "2022-08", "has_results": false, "last_update_posted_date": "2020-11-04", "last_synced_at": "2026-10-31T12:29:26.815Z", "location_count": 1, "location_summary": "New Haven, Connecticut", "locations": [ { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT04615091" }, { "nct_id": "NCT06159491", "title": "Pacritinib in CMML", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Chronic Myelomonocytic Leukemia" ], "interventions": [ { "name": "Pacritinib", "type": "DRUG" }, { "name": "Azacitidine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Douglas Tremblay", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 26, "start_date": "2024-09-18", "completion_date": "2028-01", "has_results": false, "last_update_posted_date": "2026-08-11", "last_synced_at": "2026-10-31T12:29:26.815Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06159491" }, { "nct_id": "NCT02707991", "title": "Nurse Case Management to Improve Hepatitis C Care in HIV Co-infection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "HIV", "Hepatitis C, Chronic" ], "interventions": [ { "name": "Nurse Case Management", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Johns Hopkins University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 68, "start_date": "2016-07", "completion_date": "2018-08", "has_results": true, "last_update_posted_date": "2019-05-02", "last_synced_at": "2026-10-31T12:29:26.815Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02707991" }, { "nct_id": "NCT04629976", "title": "Activity of NCO-48 Fumarate in Treatment-Naive Adults With Chronic Hepatitis B", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Chronic Hepatitis B" ], "interventions": [ { "name": "NCO-48 Fumarate 4 mg", "type": "DRUG" }, { "name": "NCO-48 Fumarate 20 mg", "type": "DRUG" }, { "name": "Tenofovir Alafenamide 25 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nucorion Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 21, "start_date": "2021-01-12", "completion_date": "2022-12-28", "has_results": false, "last_update_posted_date": "2023-01-04", "last_synced_at": "2026-10-31T12:29:26.815Z", "location_count": 1, "location_summary": "Monterey Park, California", "locations": [ { "city": "Monterey Park", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04629976" }, { "nct_id": "NCT00096018", "title": "Fludarabine and Thalidomide in Treating Patients With Newly Diagnosed Chronic Lymphocytic Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Leukemia" ], "interventions": [ { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "thalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 43, "start_date": "2002-05", "completion_date": "2012-05", "has_results": true, "last_update_posted_date": "2013-10-24", "last_synced_at": "2026-10-31T12:29:26.815Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00096018" }, { "nct_id": "NCT04143243", "title": "One-day Life Skills Workshop for Veterans With TBI, Pain, and Psychopathology: Evaluating Efficacy and Mechanism of Change", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Traumatic Brain Injury", "Chronic Pain", "Post Traumatic Stress Disorder", "Depression", "Anxiety" ], "interventions": [ { "name": "ACT on Life", "type": "BEHAVIORAL" }, { "name": "Education, Resources, and Support", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "VA Office of Research and Development", "sponsor_class": "FED", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 176, "start_date": "2020-07-01", "completion_date": "2024-08-03", "has_results": true, "last_update_posted_date": "2025-10-08", "last_synced_at": "2026-10-31T12:29:26.815Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04143243" }, { "nct_id": "NCT03573817", "title": "A 42-day Parallel Group Safety Study of Revefenacin and Formoterol, Administered in Sequence and as a Combination, in Participants With COPD", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Obstructive Pulmonary Disease (COPD)" ], "interventions": [ { "name": "Revefenacin", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Formoterol", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mylan Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 122, "start_date": "2018-05-31", "completion_date": "2018-09-25", "has_results": true, "last_update_posted_date": "2022-02-24", "last_synced_at": "2026-10-31T12:29:26.815Z", "location_count": 12, "location_summary": "Miami, Florida • Orlando, Florida • Sarasota, Florida + 9 more", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Saint Charles", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT03573817" } ] }